Die Blutvergiftung ist die dritthäufigste Todesursache in Deutschland. Mithilfe eines neuen, zylinderförmigen Apparates könnten Ärzte möglicherweise mehr Menschen retten. Folge eins unserer Serie über medizinische Innovationen.
|
Brean Capital analyst Jonathan Aschoff was out pounding the table on Cytosorbents Corp (NASDAQ:CTSO) Thursday, reiterating a Buy rating and price target of $25, which implies an upside of 172% from current levels:
From PubMede, Int. Journal of art. Organs, 2015 Feb 3;0(0):0. doi: 10.5301/ijao.5000382. [Epub ahead of print]
First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report.
PURPOSE: A new hemoadsorption device intended as adjunctive treatment for patients with elevated cytokine levels in the setting of SIRS and sepsis has shown promising results. We report on the beneficial application of the device in a patient with cardiogenic septic shock receiving combined extracorporeal life support with rECMO, LVAD, and CVVH despite his highly septic condition.
METHODS: A 39-year-old patient presented with fulminant ARDS and cardiogenic septic shock. A veno-arterial ECMO was implanted for circulatory support. During the course of illness, the patient developed acute renal failure in addition to his chronic renal insufficiency, making initiation of CVVH necessary. Due to a complete cardiac arrest in both ventricles, a left ventricular assist device (LVAD) in combination with right ECMO (rECMO) was implanted despite manifest septic conditions. In the post-operative course IL-6 levels and vasopressor dosages increased drastically. A CytoSorb hemoadsorption device was therefore installed in the CVVH circuit and 3 sessions were run during the following 4 days.
RESULTS: During CytoSorb treatment, inflammatory markers IL-6, procalcitonin, and C-reactive protein decreased concomitant with significantly reduced vasopressor support. No adverse device-related side effects were documented during or after the treatment sessions.
CONCLUSIONS: This is the first clinical case report of a highly septic patient treated with the combined use of LVAD, rECMO, CVVH, and CytoSorb. The combination was practical, technically feasible, and beneficial for the patient. This combination represents a reasonable approach to improve survival in patients with multiple organ dysfunction necessitating several organ supportive techniques.
Quelle: Nasdaq-Message-Board
Research analysts at Brean Capital set a $25.00 target price on shares of Cytosorbents Corporation (NASDAQ:CTSO) stock in a report released on Thursday. The firm currently has a a “buy” rating on the stock. Cytosorbents Corporation (NASDAQ:CTSO) in last trading activity moved up 10.01% to close at $10.00. Company weekly performance is 24.07%. Cytosorbents Corporation (NASDAQ:CTSO) is -22.30% away from its 52 week high.
MLV analyst Raghuram Selvaraju came out today with an extremely bullish call on Cytosorbents Corp (NASDAQ:CTSO), initiating a Buy rating and a $30 price target, which represents a potential upside of 170% from where the stock is currently trading. Cytosorbents shares are trading down $0.08 or 0.74% to $10.79.
Selvaraju wrote, “In our view, CytoSorbents is an unusual technology platform firm with a marketed product in Europe that is applicable across several indications in the hospitalbased sector. This product, CytoSorb®, has already generated positive proof-ofconcept data and could achieve regulatory approval in the U.S. next ...
MONMOUTH JUNCTION, N.J., March 24, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, will report fiscal 2014 financial results after the market close on Tuesday, March 31, 2015.
CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2014 and fiscal year ending December 31, 2014, and answer pre-submitted questions as time permits.
finance.yahoo.com/news/...fiscal-2014-operating-110000422.html
Ein schwaches 4. Quartal aufgrund Problemen im Direktvertrieb und einer daraus resultierenden Restrukturierung schickt den Kurs allerdings in den Keller
www.prnewswire.com/news-releases/...ers-meeting-300154052.html
luvboats2003 • 1 hour 40 minutes ago Flag
Boom! The spectral killer. Cytosorb now covers the endotoxin from gram negative bacteria. It also kills the fear mongers that harp on the fact that some of the Cytosorb early patents are expiring soon, as these new patents will reset the clock on the Cytosorb technology exclusivity.
Once again I will point out a Brown university article on the subject of endotoxins and sepsis, search: Brown.edu "Sepsis Drug Fails To Help In Clinical Trial"
It is an article about Eritotran, an anti-endotoxin drug that was clinically effectively at removing endotoxins but failed to help people with established septic shock. Note the section titled "Overall, what did you find".
"The drug is very effective as an anti-endotoxin but it didn’t work if you give it to someone who is already infected and in established septic shock. That, of course was the hope, that we could still rescue people who were desperately ill, but we saw no signal whatsoever. It didn’t work, period. To me it answered the question, which has been around for over 100 years."
So even when endotoxins are effectively eradicated, it may still be too late to stop the cytokine storm. Cytosorb-XL now covers both the endotoxins and the cytokine storm!!!
Habe obenstehenden Beitrag aus dem CTSO-Board bei Yahoo entnommen. Es geht offenbar bei CytoSorb XL um eine Anwendungserweiterung auf Endotoxin in Verbindung mit der Bekämpfung des Zytokin-Sturms. Das würde die Einsatzmöglichkeiten erheblich erweitern und verbessern.
Mals sehen wie sich die Meldung auf die heutige Kursentwicklung auswirkt!?
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 98 | Der Stabilisator (auch fürs Depot?) | erfg | xxtpat | 25.04.21 01:42 | |
32 | European Union Regulatory Approval for CytoSorb | 0815ax | Laserfuzzy | 13.09.13 16:12 | ||
27 | MedaSorb Technologies Corp. ( WKN: A0KEY3 / MSBT ) | 0815ax | Dr.Watson-09 | 11.06.10 18:17 | ||
16 | Medasorb Tech.Corb | siggileder | jocyx | 21.10.09 10:52 | ||
1 | Niemand einen Rat?? | kult | kult | 15.05.07 14:56 |